Research programme: RNA targeted compounds - Agouron/Abbott Laboratories
Alternative Names: IBIS-00560146Latest Information Update: 22 Sep 2006
At a glance
- Originator Agouron Pharmaceuticals; Ibis Therapeutics
- Class
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Cancer; Hepatitis C
Most Recent Events
- 22 Sep 2006 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 22 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 22 Sep 2006 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)